The Week

LABU.US fell 13.92% this week to $261.30, while the S&P 500 slipped 0.8%, leaving the ETF about 13.12 percentage points behind the benchmark. The week was a fade from the top: Tuesday opened at $287.83 and touched $300.50 before drifting lower through Thursday, which broke below $270, and Friday closed at the weekly low of $261.30, with a 14.07% intraweek range.

SPDR S&P Biotech This Week

The underlying SPDR S&P Biotech (XBI.US) lost 4.65% this week to $156.20, also lagging the S&P 500. It followed a similar pattern: Tuesday opened at $160.765, the high of $163.43 came midweek, and Friday drifted down to $156.20 by the close, for a 4.73% range and a broadly softer tone.

Leverage & Decay

LABU tracks three times the daily move of SPDR S&P Biotech. The underlying dropped 4.65% this week; a simple three-times read gives a theoretical loss of about 13.95%, while LABU actually fell 13.92%, a gap of just 0.03 percentage points. That gap reflects daily rebalancing: the product replicates three times each day’s move, not three times the weekly return. With the underlying trending lower, the single-direction path kept decay small. If price action turns choppy, rebalancing costs would widen and long-term returns can drift away from three times the underlying.

SPDR S&P Biotech News

The sector had a heavy news week. Revolution Medicines’ daraxonrasib approval and NEJM data drew attention, and Veru advanced oral Sabizabulin toward a planned Phase 2 trial. Roivant Sciences picked up buy ratings from Jefferies and TD Cowen after its mosliciguat PHocus data in PH-ILD, while several directors sold shares during the week. A hotter CPI report pushed the market-implied odds of a Fed rate hike at the 16 September meeting to nearly 90%, pressing high-beta biotech names alongside the broader market.

The Week Ahead

The macro calendar dominates. Before the Fed meeting on 16 September, retail sales, the NAHB housing index, and weekly EIA crude inventories will land, and rate-hike expectations are weighing on high-beta exposure. For LABU, the focus is whether SPDR S&P Biotech can stabilise near $156 and how the sector responds to the rate backdrop.

In Short

LABU’s loss this week was nearly three times the underlying’s drop, with minimal decay, showing the product tracked its daily leverage closely in a trending tape. Biotech had clinical news support, but hotter rate expectations and director selling created a crosscurrent, leaving SPDR S&P Biotech lower. The next test is whether the Fed outcome amplifies high-beta swings and whether biotech holds the $156 area.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.